organization · Reporting owner
ABG Management Ltd.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MedAvail Holdings, Inc.MDVL · Entity 94590 | 10% owner | June 16, 2023 | June 21, 2023 |
| ProMIS Neurosciences Inc.PMN · Entity 6643 | 10% owner | February 03, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MedAvail Holdings, Inc.
Report date June 16, 2023 · Filed June 21, 2023
Jointly reported with ABG WTT-MedAvail Ltd, Ally Bridge Group-WTT Global Life Science Capital Partners, L.P., ABG-WTT Global Life Science Capital Partners GP, L.P., ABG-WTT Global Life Science Capital Partners GP Ltd, Yu Fan, Ally Bridge MedAlpha Master Fund L.P., Ally Bridge Group (NY) LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2028-06-16 | IndirectSee footnote | 6,818,181 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Other · Acquired 6,818,181 · Balance 6,818,181 F1: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F2: These securities are held of record by ABG WTT. ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. |
| Series A Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2028-06-16 | IndirectSee footnote | 965,130 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Other · Acquired 965,130 · Balance 965,130 F1: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F3: These securities are held of record by MedAlpha. Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023.
F2: These securities are held of record by ABG WTT. ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
F3: These securities are held of record by MedAlpha. Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.
ProMIS Neurosciences Inc.
Report date February 03, 2026 · Filed February 06, 2026
Jointly reported with Ally Bridge MedAlpha Master Fund L.P., Ally Bridge Group (NY) LLC, Yu Fan, Alex Slanix Paul
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 943,090 |
Reported balance
After 2026-02-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-03 · Purchase · Acquired 700,741 · Balance 943,090 F1: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. F2: The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited. F3: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. F4: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. F5: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $14.40 | IndirectSee Footnote | 700,741 |
Reported balance
After 2026-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-03 · Purchase · Acquired 700,741 · Balance 700,741 F1: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. F6: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310. F3: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. F4: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. F5: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. F7: The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.
F2: The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.
F3: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.
F4: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.
F5: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.
F6: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.
F7: The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 6, 2026 00:00 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseWarrants · Derivative | 700,741 | Not disclosed Strike: $14.40 | Not disclosed |
DisclosureSEC source: 0001493152-26-005410 · ownership.xml · derivative · entry 2 ABG Management Ltd. · CIK 0001832106 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Alex Slanix Paul · CIK 0002092283 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 700,741 Underlying: Common Shares · 700,741 shares Expires not disclosed F1 · price: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. F6 · derivative.exercise_date: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310. F6 · derivative.expiration_date: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310. F3 · ownership.nature: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. F4 · ownership.nature: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. F5 · ownership.nature: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. F7 · ownership.nature: The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:00 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 700,741 | $12.13 | $8,499,988.33 |
DisclosureSEC source: 0001493152-26-005410 · ownership.xml · nonDerivative · entry 1 ABG Management Ltd. · CIK 0001832106 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Alex Slanix Paul · CIK 0002092283 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 943,090 F1 · price: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. F2 · ownership.nature: The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited. F3 · ownership.nature: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. F4 · ownership.nature: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. F5 · ownership.nature: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:34 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001493152-25-019320 · ownership.xml · derivative · entry 1 ABG Management Ltd. · CIK 0001832106 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Alex Slanix Paul · CIK 0002092283 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2035-10-22 F1 · derivative.exercise_date: 25% of the shares subject to this option vested on the date of grant and the remaining shares shall vest in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F2 · ownership.direct: This option was granted to Slanix Alex, a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. Dr. Alex holds any equity-based compensation awarded to him for his service as a director of the Issuer for the benefit of Ally Bridge MedAlpha Master Fund L.P. Any proceeds from the sale of shares upon exercise of this award shall be remitted to Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 16:05 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | OtherSeries A Warrant (Right to Buy) · Derivative | 965,130 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0000899243-23-016125 · doc4.xml · derivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 965,130 Underlying: Common Stock · 965,130 shares Expires 2028-06-16 F1 · kind: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F1 · price: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F3 · ownership.nature: These securities are held of record by MedAlpha. Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 16:05 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | OtherSeries A Warrant (Right to Buy) · Derivative | 6,818,181 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0000899243-23-016125 · doc4.xml · derivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,818,181 Underlying: Common Stock · 6,818,181 shares Expires 2028-06-16 F1 · kind: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F1 · price: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F2 · ownership.nature: These securities are held of record by ABG WTT. ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchasePre-Funded Warrant (Right to Buy) · Derivative | 965,130 | $0.32 Strike: $0.00 | $309,999.76 |
DisclosureSEC source: 0000899243-23-008565 · doc4.xml · derivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 965,130 Underlying: Common Stock · 965,130 shares Expires not disclosed F1 · derivative.exercise_date: Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023. F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire. F4 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchasePre-Funded Warrant (Right to Buy) · Derivative | 6,818,181 | $0.32 Strike: $0.00 | $2,189,999.74 |
DisclosureSEC source: 0000899243-23-008565 · doc4.xml · derivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,818,181 Underlying: Common Stock · 6,818,181 shares Expires not disclosed F1 · derivative.exercise_date: Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023. F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire. F3 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseWarrant (Right to Buy) · Derivative | 1,487,058 | $1.06 Strike: $1.25 | $1,579,999.13 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · derivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,487,058 Underlying: Common Stock · 1,487,058 shares Expires 2027-04-04 F2 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. As a result of an internal reorganization, Ally Bridge MedAlpha Management L.P. and Ally Bridge MedAlpha Management GP, LLC are no longer deemed to share beneficial ownership of the securities reported herein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseWarrant (Right to Buy) · Derivative | 5,571,764 | $1.06 Strike: $1.25 | $5,919,999.25 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · derivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,571,764 Underlying: Common Stock · 5,571,764 shares Expires 2027-04-04 F1 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 2,974,117 | $1.06 | $3,159,999.31 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,894,897 F2 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. As a result of an internal reorganization, Ally Bridge MedAlpha Management L.P. and Ally Bridge MedAlpha Management GP, LLC are no longer deemed to share beneficial ownership of the securities reported herein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 11,143,529 | $1.06 | $11,839,999.56 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,029,480 F1 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:31 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 5,727 | $15.00 | $85,881.52 |
DisclosureSEC source: 0000899243-21-000379 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,920,780 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.83 to $15.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:31 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 6,943 | $15.00 | $104,116.53 |
DisclosureSEC source: 0000899243-21-000379 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,885,951 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.83 to $15.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 45 | $14.00 | $630.00 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,915,053 F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 55 | $14.00 | $770.00 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,879,008 F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 3,213 | $13.98 | $44,906.82 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,915,008 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.85 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 3,894 | $13.98 | $54,424.88 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,878,953 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.85 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 4,019 | $13.99 | $56,233.45 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 6 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,911,795 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.90 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 4,871 | $13.99 | $68,154.54 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 5 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,875,059 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.90 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 9,810 | $13.99 | $137,207.57 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,907,776 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.91 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 11,890 | $13.99 | $166,299.49 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,870,188 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.91 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 7,661 | $13.70 | $104,967.96 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,897,966 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.45 to $13.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 9,287 | $13.70 | $127,246.76 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,858,298 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.45 to $13.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 7,358 | $13.31 | $97,969.56 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,890,305 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 8,919 | $13.31 | $118,753.81 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,849,011 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 8,408 | $13.59 | $114,303.40 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,882,947 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.38 to $13.84. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 10,192 | $13.59 | $138,556.16 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,840,092 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.38 to $13.84. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 1,029 | $14.00 | $14,406.00 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 6 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,874,539 F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 1,248 | $14.00 | $17,472.00 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 5 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,829,900 F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 5,731 | $13.12 | $75,191.29 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,873,510 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 6,946 | $13.12 | $91,132.21 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,828,652 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 12,851 | $13.06 | $167,848.20 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,867,779 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 15,578 | $13.06 | $203,465.82 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,821,706 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 9,027 | $13.08 | $118,092.12 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 6 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,854,928 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 10,942 | $13.08 | $143,144.34 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 5 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,806,128 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 4,276 | $12.50 | $53,430.76 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,845,901 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.29 to $12.995. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 5,184 | $12.50 | $64,776.67 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,795,186 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.29 to $12.995. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 6,535 | $12.24 | $80,016.50 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,841,625 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.0125 to $12.62. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 7,922 | $12.24 | $96,999.34 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,790,002 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.0125 to $12.62. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.